Interactive Brokers shares jump as it secures spot in S&P 500
In a recent transaction reported to the Securities and Exchange Commission, Yann Echelard, a director at TG Therapeutics, Inc. (NASDAQ:TGTX), sold 10,000 shares of the company’s common stock. The shares were sold on June 13, 2025, at a weighted average price of $36.94, resulting in a total sale value of $369,400. The transaction comes as TG Therapeutics, currently valued at $5.2 billion, shows strong momentum with an 18% gain year-to-date, despite recent volatility. According to InvestingPro analysis, the company maintains a "GREAT" financial health score.
According to the filing, these shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations. Following this transaction, Echelard holds 228,816 shares of TG Therapeutics’ common stock. The company’s strong fundamentals are reflected in its impressive 87% gross profit margin, though InvestingPro analysis indicates the stock is currently trading above its Fair Value. Investors can access 12 additional exclusive ProTips and a comprehensive Pro Research Report for deeper insights into TGTX’s valuation and growth prospects.
Additionally, on June 12, 2025, Echelard was granted 14,718 restricted shares, which will vest on June 12, 2026. This grant was recorded at no cost. After these transactions, Echelard’s total holdings, including restricted shares, amount to 238,816 shares. The company has demonstrated solid performance with a 115% return over the past year, while maintaining a healthy current ratio of 4.02, indicating strong liquidity.
In other recent news, TG Therapeutics reported its first-quarter 2025 earnings, revealing a significant miss on earnings per share (EPS) but a slight beat on revenue expectations. The company’s EPS came in at $0.03, falling short of the forecasted $0.16, while revenue reached $119.7 million, surpassing the $117.13 million estimate. Despite the EPS miss, the company demonstrated robust revenue growth, reporting a 137% year-over-year increase. TG Therapeutics has raised its full-year 2025 U.S. net revenue guidance from $525 million to $560 million. In other developments, TG Therapeutics shareholders approved key proposals at the 2025 Annual Meeting, including the election of six directors and the ratification of KPMG LLP as the independent registered public accounting firm. Additionally, Jefferies analyst Roger Song maintained a Buy rating on TG Therapeutics with a price target of $46.00, highlighting the company’s strong financial position. Moreover, the company shared updates on its multiple sclerosis drug BRIUMVI at a recent medical conference, emphasizing the drug’s safety and tolerability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.